{"entity":{"id":"idea-data-external-control-arm-standard","kind":"idea","name":"Standards for external control arms built from federated real-world data","aka":[],"tldr":"When a trial has no comparison group, the comparison is sometimes built from old patient records. Set rules for how that is done so the answer is not rigged.","summary":"External control arms from real-world or historical trial data are increasingly used in rare cancers and single-arm approvals, with inconsistent methods. The proposal defines standards: pre-specification before trial unblinding, construction from federated data with documented eligibility mapping, minimum covariate set, quantitative bias analysis and tipping-point sensitivity analyses, plus public deposition of the control cohort definition. Regulatory guidance (FDA 2023 draft on externally controlled trials) is the starting point.","asOf":"2026-09-08","links":[{"label":"Bottleneck evidence (Weak real-world evidence and registries): Gyawali, Hey & Kesselheim, Assessment of the clinical benefit of cancer drugs receiving accelerated approval (JAMA Intern Med 2019)","url":"https://doi.org/10.1001/jamainternmed.2019.0462"}],"tags":[],"related":[],"cancers":[],"sections":["ai-computation"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["real-world-evidence","basket-umbrella-platform"],"trials":[],"people":[],"bottlenecks":["b-real-world-evidence","b-trial-design","b-rare-cancers"],"keyPapers":["paper-gyawali-jama-intern-med"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Standardised external controls will reduce the discrepancy between single-arm effect estimates and subsequent randomised confirmation by half.","rationale":"Several single-arm approvals with historical controls were later contradicted by randomised trials; the failures trace to unmeasured confounding and cherry-picked comparators, both addressable by pre-specification and bias analysis.","test":"Reconstruct external controls under the standard for ten single-arm approvals that later had randomised confirmation; compare the standardised estimate with the randomised result.","maturity":"early-clinical","actor":"regulator","cost":"small","horizonYears":2},"route":"/ideas/idea-data-external-control-arm-standard/","neighbours":{"section":[{"id":"ai-computation","kind":"section","name":"AI & Computation","route":"/fronts/ai-computation/"}],"term":[{"id":"basket-umbrella-platform","kind":"term","name":"Basket, umbrella, and platform trials","route":"/terms/basket-umbrella-platform/"},{"id":"real-world-evidence","kind":"term","name":"Real-world evidence","route":"/terms/real-world-evidence/"}],"bottleneck":[{"id":"b-rare-cancers","kind":"bottleneck","name":"Rare and paediatric cancers without markets","route":"/bottlenecks/b-rare-cancers/"},{"id":"b-trial-design","kind":"bottleneck","name":"Trial design, endpoints and cost","route":"/bottlenecks/b-trial-design/"},{"id":"b-real-world-evidence","kind":"bottleneck","name":"Weak real-world evidence and registries","route":"/bottlenecks/b-real-world-evidence/"}],"paper":[{"id":"paper-gyawali-jama-intern-med","kind":"paper","name":"Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval","route":"/key-papers/paper-gyawali-jama-intern-med/"}]}}